Olanzapine is a new antipsychotic agent with serotonin/dopamine antagonism action. Efficacy in treating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score was demonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparable or superior to haloperidol. Superior efficacy for negative and depressive symptoms was shown in comparison to haloperidol. Olanzapine has a favorable acute and tardive extrapyramidal symptom profile relative to haloperidol and caused substantially less elevation of serum prolactin. Dose- related weight gain and asymptomatic mild transaminase elevations occurred in olanzapine-treated patients.
|Number of pages||5|
|Journal||Journal of Clinical Psychiatry|
|Issue number||SUPPL. 10|
|State||Published - Aug 20 1997|
ASJC Scopus subject areas
- Psychiatry and Mental health
- Clinical Psychology